PANCREATIC CANCER

Metabolite crosstalk could modulate chemotherapy response in pancreatic cancer

Macrophages are highly abundant in the microenvironment of pancreatic ductal adenocarcinoma (PDAC), with reported roles of tumour-associated macrophages (TAMs) in chemotherapy resistance. New research now provides clues to the influence of TAMs in pancreatic cancer therapy, demonstrating that pyrimidine nucleoside release (notably deoxycytidine) from macrophages inhibits the effectiveness of gemcitabine treatment of pancreatic cancer. Macrophages programmed by PDAC cells released a spectrum of pyrimidine species, including deoxycytidine, in vitro. Crucially, deoxycytidine inhibited gemcitabine, directly competing with drug uptake and metabolism. In mouse models of PDAC, genetic or pharmacological depletion of TAMs sensitized these tumours to gemcitabine treatment.

References

Original article

  1. Halbrook, C. J. et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. https://doi.org/10.1016/j.cmet.2019.02.001 (2019)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Metabolite crosstalk could modulate chemotherapy response in pancreatic cancer. Nat Rev Gastroenterol Hepatol 16, 262 (2019). https://doi.org/10.1038/s41575-019-0143-9

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing